Adhesion-GPCRs pp 138-148 | Cite as

The Role of CD97 in Regulating Adaptive T-Cell Responses

  • Ian Spendlove
  • Ruhcha Sutavani
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 706)


CD97 was identified as an early activation marker on T cells, having low expression on naive T cells. This is a common feature of molecules that have a role in T-cell function. It was subsequently identified as a ligand for CD55, which has been previously identified as an innate regulator of complement. The interaction of this receptor-ligand pair has been shown to provide a potent costimulatory signal to human T cells, despite their modest affinity. Though both CD97 and CD55 are expressed on T cells as well as antigen presenting cells (APCs), their interaction is significant when CD97 on APCs interacts with CD55 on T cells. The converse interaction is poorly defined and may be less significant. A unique aspect of the interaction of CD97 with CD55 is the stimulation of naive T cells, leading to the induction of IL-10 producing cells that behave like Tr1 regulatory cells. This raises a number of questions regarding the dual functions of CD55; regulating complement and stimulating T cells via CD97 interaction and any potential overlap in the consequences of these dual roles.


Costimulatory Molecule CD97 Interaction CD28 Costimulation Short Consensus Repeat Early Activation Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eichler W, Aust G, Hamann D. Characterization of an early activation-dependent antigen on lymphocytes defined by the monoclonal antibody BL-Ac(F2). Scand J Immunol 1994; 39(1):111–115.PubMedCrossRefGoogle Scholar
  2. 2.
    Kop EN, Matmati M, Pouwels W et al. Differential expression of CD97 on human lymphocyte subsets and limited effect of CD97 antibodies on allogeneic T-cell stimulation. Immunology Letters 2009; 123(2):160–168.PubMedCrossRefGoogle Scholar
  3. 3.
    Lukacik P, Roversi P, White J et al. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc Natl Acad Sci USA 2004; 101(5):1279–1284.PubMedCrossRefGoogle Scholar
  4. 4.
    Abbott RJ, Spendlovel, Roversi P et al. Structural and functional characterization of a novel T-cell receptor coregulatory protein complex, CD97-CD55. J Biol Chem 2007; 282(30):22023–22032.PubMedCrossRefGoogle Scholar
  5. 5.
    Lin HH, Stacey M, Saxby C et al. Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem 2001; 276(26):24160–24169.PubMedCrossRefGoogle Scholar
  6. 6.
    Hamann J, van Zeventer C, Bijl A et al. Molecular cloning and characterization of mouse CD97. Int Immunol 2000; 12(4):439–448.PubMedCrossRefGoogle Scholar
  7. 7.
    Qian YM, Haino M, Kelly K et al. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 1999; 98(2):303–311.PubMedCrossRefGoogle Scholar
  8. 8.
    Borowski AB, Boesteanu AC, Mueller YM et al. Memory CD8+ T-cells require CD28 costimulation. J Immunol 2007; 179(10):6494–6503.PubMedGoogle Scholar
  9. 9.
    Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3(8):609–620.PubMedCrossRefGoogle Scholar
  10. 10.
    Shahinian A, Pfeffer K, Lee KP et al. Differential T-cell costimulatory requirements in CD28-deficient mice. Science 1993; 261(5121):609–612.PubMedCrossRefGoogle Scholar
  11. 11.
    Yashiro Y, Tai XG, Toyo-oka K et al. A fundamental difference in the capacity to induce proliferation of naive T-cells between CD28 and other costimulatory molecules. Eur J Immunol 1998; 28(3):926–935.PubMedCrossRefGoogle Scholar
  12. 12.
    Capasso M, Durrant LG, Stacey M et al. Costimulation via CD55 on Human CD4+ T-Cells Mediated by CD97. J Immunol 2006; 177(2): 1070–1077.PubMedGoogle Scholar
  13. 13.
    Spendlove I, Ramage JM, Bradley R et al. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol Immunother 2006; 55(8):987–995.PubMedCrossRefGoogle Scholar
  14. 14.
    Acuto O, Michel F. CD28-mediated costimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3(12):939–951.PubMedCrossRefGoogle Scholar
  15. 15.
    Jordan MS, Singer AL, Koretzky GA. Adaptors as central mediators of signal transduction in immune cells. Nat Immunol 2003; 4(2):110–116.PubMedCrossRefGoogle Scholar
  16. 16.
    Rudd CE, Raab M. Independent CD28 signaling via VAV and SLP-76: a model for in trans costimulation. Immunol Rev 2003; 192:32–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Kane LP, Lin J, Weiss A. It’s all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. Trends Immunol 2002; 23(8):413–420.PubMedCrossRefGoogle Scholar
  18. 18.
    Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355(10):1018–1028.PubMedCrossRefGoogle Scholar
  19. 19.
    Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8+ T-cell proliferation and lead to the amplification in vivo of cytotoxic T-cell responses. J Exp Med 1997; 186(1):47–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Hoffman EM. Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. Immunochemistry 1969; 6(3):391–403.PubMedCrossRefGoogle Scholar
  21. 21.
    Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160(5):1558–1578.PubMedCrossRefGoogle Scholar
  22. 22.
    Nicholson-weller A, Wang C. Structure and function of decay-accelerating factor Cd55. J Lab Clin Med 1994; 123(4):485–491.PubMedGoogle Scholar
  23. 23.
    Harris CL, Spiller OB, Morgan BP. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities [In Process Citation]. Immunology 2000; 100(4):462–470.PubMedCrossRefGoogle Scholar
  24. 24.
    Brodbeck WG, Kuttner-Kondo L, Mold C et al. Structure/function studies of human decay-accelerating factor. Immunology 2000; 101(1):104–111.PubMedCrossRefGoogle Scholar
  25. 25.
    Harris CL, Abbott RJ, Smith RA et al. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem 2005; 280(4):2569–2578.PubMedCrossRefGoogle Scholar
  26. 26.
    Kuttner-Kondo L, Hourcade DE, Anderson VE et al. Structure-based mapping of DAF’s active site residues that decay accelerate the C3 convertases. J Biol Chem 2007.Google Scholar
  27. 27.
    Sangiorgio V, Pitto M, Palestini P et al. GPI-anchored proteins and lipid rafts. Ital J Biochem 2004; 53(2):98–111.PubMedGoogle Scholar
  28. 28.
    Lund-Johansen F, Olweus J, Symington FW et al. Activation of human monocytes and granulocytes by monoclonal antibodies to glycosylphosphatidylinositol-anchored antigens. Eur J Immunol 1993; 23(11):2782–2791.PubMedCrossRefGoogle Scholar
  29. 29.
    Shenoy-Scaria AM, Kwong J, Fujita T et al. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol 1992; 149(11):3535–3541.PubMedGoogle Scholar
  30. 30.
    Shibuya K, Abe T, Fujita T. Decay-accelerating factor functions as a signal transducing molecule for human monocytes. J Immunol 1992; 149(5):1758–1762.PubMedGoogle Scholar
  31. 31.
    Davis LS, Patel SS, Atkinson JP et al. Decay-accelerating factor functions as a signal transducing molecule for human T-cells. J Immunol 1988; 141(7):2246–2252.PubMedGoogle Scholar
  32. 32.
    Tosello AC, Mary F, Amiot M et al. Activation of T-cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion. J Inflamm 1998; 48(1):13–27.PubMedGoogle Scholar
  33. 33.
    Heeger PS, Lalli PN, Lin F et al. Decay-accelerating factor modulates induction of T-cell immunity. J Exp Med 2005; 201(10):1523–1530.PubMedCrossRefGoogle Scholar
  34. 34.
    Lalli PN, Strainic MG, Lin F et al. Decay accelerating factor can control T-cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 2007; 179(9):5793–5802.PubMedGoogle Scholar
  35. 35.
    Lalli PN, Strainic MG, Yang M et al. Locally produced C5a binds to T-cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 2008; 112(5):1759–1766.PubMedCrossRefGoogle Scholar
  36. 36.
    Liu J, Miwa T, Hilliard B et al. The complement inhibitory protein DAF (CD55) suppresses T-cell immunity in vivo. J Exp Med 2005; 201(4):567–577.PubMedCrossRefGoogle Scholar
  37. 37.
    Toomey CB, Cauvi DM, Song W-C et al. Decay-accelerating factor 1 (Daf1) deficiency exacerbates xenobiotic-induced autoimmunity. Immunology 2010; Epub ahead of Print.Google Scholar
  38. 38.
    Strainic MG, Liu J, Huang D et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T-cells. Immunity 2008; 28(3):425–435.PubMedCrossRefGoogle Scholar
  39. 39.
    Veninga H, Becker S, Hoek RM et al. Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol 2008; 181(9):6574–6583.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ian Spendlove
    • 1
  • Ruhcha Sutavani
  1. 1.Academic Clinical Oncology, The City HospitalThe University of NottinghamNottinghamUK

Personalised recommendations